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Abstract: This paper presents an advanced Internet of Things point-of-care bio-fluid analyzer; a LoRa/Bluetooth-enabled 
electronic reader for biomedical strip-based diagnostics system for personalized monitoring. We undertake test simulations 
(technology trial without patient subjects) to demonstrate potential of long-range analysis, using a disposable test ‘key’ and 
companion Android app to form a diagnostic platform suitable for remote point-of-care screening for urinary tract infection. The 
868 MHz LoRaWAN-enabled personalized monitor demonstrated sound potential with UTI test results being correctly 
diagnosed and transmitted to a remote secure cloud server in every case. Tests ranged over distances of 1.1-6.0 Km with radio 
path losses from 119-141 dB. All tests conducted were correctly and robustly received at the base station and relayed to the 
secure server for inspection. The UTI test strips were visually inspected for correct diagnosis based on color change and verified 
as 100% accurate. Results from testing across a number of regions indicate that such an Internet of Things medical solution is a 
robust and simple way to deliver next generation community-based smart diagnostics and disease management to best benefit 
patients and clinical staff alike. This significant step can be applied to any type of home or region, particularly those lacking 
suitable mobile signals, broadband connections, or even landlines. It brings subscription-free long-range bio-telemetry to 
healthcare providers and offers savings on regular clinician home visits or frequent clinic visits by the chronically ill. This work 
highlights practical hurdles in establishing an Internet of Medical Things network, assisting informed deployment of similar 
future systems. 
 
Index Terms—Clinical Diagnostics, Internet of Things, LoRa, Remote Healthcare, Sensor networks, Urinary Tract Infection.  
 
I. INTRODUCTION1 
HE Internet of Things (IoT) is expected to have a 
disruptive impact across industry and society, with 20.8 
billion IoT connected devices forecast by 2020 [1]. The 
Internet of Things seeks to inter-connect many physical 
devices such as vehicles, consumer electronics, buildings, 
environmental sensors, etc. to facilitate the collection and 
exchange of data. The IoT market size is predicted to grow 
from USD 157.05 billion in 2016 to USD 661.74 billion by 
2021, a growth driven by the proliferation of smarter and 
more cost-effective sensors, the emergence of cloud 
computing, and the maturity and expanse of the high speed 
internet [2]. Global investment will expedite the 
propagation of Internet of Things technologies; for 
example, Chinese manufacturers have asserted that in the 
coming years they will spend an annual $127b on IoT 
devices and infrastructure [3]. 
Significant recent interest in Wireless Sensor networks 
(the key enabler for IoT-based systems) including 
developing effect routing protocols, and a range of 
applications including medical imaging [4, 5]. Further work 
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has been done to explore emerging new and emerging 
wireless network strategies with an amount of work 
tackling IoT network developments [6-10] and innovations 
to create smarter IoT networks [11-14]. These, as well as 
cross-application with supporting technologies [15-17] 
helps to generate a range of novel medical applications [18] 
including imaging [19-21] and object detection [22] that 
address growing societal needs for early cancer detection 
and developing world healthcare solutions. A key to new 
remote healthcare devices is in addressing real-world issues 
with power [23-29]. 
One such enabling IoT technology is LoRa which is the 
physical layer technology (using a derivative of Chirp 
Spread Spectrum (CSS) [30] for a Low Power Wide Area 
Network (LPWAN). LoRa infrastructure has been 
developed in recent years and its expansion appears to be 
increasing in rate as more countries choose to deploy full-
coverage networks [31]. It operates in the license-free 
Industrial Scientific and Medical (ISM) radio bands with 
devices in Europe (as well as Africa, Russia, and Asia) 
operating at 868 MHz and in USA/Canada at 915 MHz [30, 
32]. Three layers of encryption ensure high levels of 
security; this is particularly significant for the transmission 
of patient’s personal data. With a maximum of 62,500 
devices per gateway (dependent on user data rates which 
can be up to 50 kbps) it allows ubiquitous IoT in urban 
areas, while its long range (20 Km) makes it ideal for 
sparsely populated regions [30]. Target sectors include 
domestic waste management, smart parking, seawater 
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Fig. 2.  Bio-fluid sample tester system with LoRa radio 
pollution measurement, electricity/water/gas meters, 
highway tolls, vending machine monitoring, golf course 
irrigation management, etc. Its key benefits include easy 
installation, subscription-free service (no mobile SIM card), 
highly secure two-way communication, long battery life (5-
10 years) and low cost [30]. These make it stand apart from 
other wireless technologies such as cell phone networks. 
LoRaWAN has been discussed, trialled, and evaluated as an 
e-Health Communication Technology [33-35], however 
none of the published material discusses using LoRaWAN 
(or any LPWAN technology) as the basis of a care home or 
domiciliary point-of-care automated test that is transmitted 
to the cloud.  
A comparison of popular IoT technologies (Table I) 
highlights such LPWAN technologies as LoRa, NB-IoT, 
EC-GSM, LTE-M, and Sigfox which boast very low power, 
low data throughput, highly secure communications, typical 
device to base-station ranges of 25Km in rural areas and 5 
Km in cities [36-46]. This technology is coming to fruition 
at a time when healthcare systems are straining due to an 
ageing population [47]. IoT-enabled remote healthcare 
devices can allow patients to return to their homes more 
quickly after a hospital stay, or to remove the need for a 
hospital stay altogether. Patients can be monitored from the 
comfort and familiarity of their own homes and clinicians 
can respond rapidly to changes in conditions. Telehealth 
monitoring has been shown to reduce Emergency Room 
visits by 15%, emergency admissions by 20%, bed days by 
14%, tariff costs by 8%, and patient death rates by a 
remarkable 45% [48]. Telehealth monitoring has also been 
shown to have predictive value in the study of early 
detection of heart failure (HF) decompensation events [49].  
Remote healthcare has attracted interest for some time [50]; 
more recently the advancing technology has increased 
potential for monitoring patients from afar. Smart homes 
fitted with multitudes of sensors can monitor the 
chronically ill continuously [51] however such expensive 
technology is not essential to monitor people at home.  IoT 
facilitated remote health monitoring system has many 
benefits over customary health monitoring system [52]. IoT 
devices can be used to enable remote health monitoring of 
patients with chronic diseases such as cardiovascular 
diseases (CVD) [53], while long-term Electrocardiogram 
(ECG) monitoring in residential environments have been 
proposed [54].    
Current challenges demand a profound restructuring of 
the global healthcare system [55] and the financial viability 
of such systems has been studied and verified [56] which 
make the vision of a ubiquitous IoT wireless sensor 
network for healthcare a valid proposition [57]. Existing 
IoT solutions for industry are relatively large and 
cumbersome; to achieve portable and wearable IoT-
healthcare devices requires effort to make the hardware less 
physically intrusive [58]. The use of IoT technologies to 
support hospital healthcare and remote monitoring has been 
presented previously [59-61], often taking the form of 
localized body-centric wireless sensor networks which relay 
data to an in-house base station which has internet 
connectivity. LPWAN IoT technologies offer connectivity 
over extended distances and are also suitable for links 
where devices are positioned indoors [62]; this has potential 
to eliminate the need for a domiciliary internet connection, 
base station, and associated equipment. The trade-off is 
with regards to the volume of data that can be relayed back 
to base [63-65]. LPWAN techniques include an array of 
technologies such as Sigfox, LoRa, LTE-M, NB-IoT, etc. 
LPWAN technology has been presented as a solution to 
monitor health and wellbeing remotely including portable 
body-worn monitoring [66]. The LoRa solution is 
particularly attractive as it requires no mobile network 
device (and thus no subscription SIM card), nor does it 
require the home to have Wi-Fi or even a land line. 
 
Fig. 1.  Block diagram of the medical LoRa network 
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The presented patient monitoring solution blends both 
emerging and developed technologies to equip the global 
healthcare system with medical solutions capable of 
meeting the growing sector demands. This work is easily 
scalable and could quickly be utilized to include futuristic 
medical body-area sensor networks [67-70]. Key drivers of 
this work include the global ageing population [47]; 
increasing volume of chronic conditions [71]; current 
international health economics; and the emergence of 
enabling technologies. The work is supported by the 
recommendations of [72] who envisage new technology as 
the key to improvements in healthcare provision, with [73] 
predicting appropriate implementation of digital technology 
in the health service could result in efficiency savings up to 
£10 billion in England alone by 2020.  
Recently there has been an amount of work published 
regarding point-of-care devices. These include the novel 
use of capacitive touch screens to detect urinary tract 
infection (UTI) to create a point-of-care device [74], the use 
of a long-range surface plasmon-polariton (LRSPP) 
waveguide biosensor for UTI detection [75], the use of 
Surface enhanced Raman Spectroscopy (SERS) to test for 
UTIs [76], a number of smartphone-based strip colorimetric 
detection systems used to remove the subjectivity of results 
interpretation [77-79] (although these are inherently 
affected by ambient light conditions and require significant 
post processing), etc.  
Other work includes the detection of Urinary Tract 
Infections on lab-on-chip device by measuring photons 
emitted from adenosine 5'-triphosphate (ATP) 
bioluminescence [80], the use of test strips to test for UTIs 
with a discussion on how an electronic reader 
(electrochemical sensor array) may be developed[81], and 
point-of-care tests for Sickle Cell Disease (SCD) [82]. 
We therefore present the findings of recent development 
activity to accomplish a remote point-of-care bio-fluid 
sample analyzer enabled with IoT capability for residential 
home use. This device employs biomarker detection strips 
using a transmission-based optical sensing technique and 
the trial focused on UTI diagnosis, with the results being 
relayed back to the attending clinician using a long-range 
IoT network (LoRa) (and simultaneously to the patient via 
Bluetooth (BLE) to the mobile app. for the patient’s 
benefit). Such a system will save money for the NHS, 
reduce patient re-admissions, and potentially saves lives 
[83]. 
 
Fig. 3. Disposable ‘key’ kit (left), sample being applied to lateral flow ‘key’ (center), and ‘key’ composite parts (right)  
 
Fig. 4.  Operational flow chart of the LoRa-enabled point-of-care system 
II. EXPERIMENTAL METHODS 
A. Network Design 
The network was set up as depicted in Fig. 1. The 
gateway (also known as the base station) that receives data 
from the medical devices was the Lorank8 from Dutch 
company Ideetron [84]. Onto this was attached a Sirio GP-
901-C 800mm high-gain omnidirectional co-linear antenna 
(1/4λ + 2×1/2λ co-linear) with a gain of 5-8.15 dBi at 868 
MHz. The gateway was connected to a computer with two 
Network Interface Controller (NIC) cards via RJ45 Ethernet 
cable; one NIC card was connected to the internet and the 
other to the Lorank8 gateway. This allowed the Lorank8 to 
communicate with the back-end secure cloud server with a 
fixed Internet Protocol (IP) address so that results appear on 
the chosen secure server and can either be read directly 
from the server using a Message Queuing Telemetry 
Transport (MQTT) client to monitor received traffic on the 
server (we used a laptop running MQTT.fx software) or 
forwarded to a visualization service to present the data in a 
user friendly manner. Use of the MQTT publish-subscribe 
telemetry protocol allows for bi-directional communication 
between a MQTT client (PC, computing device, etc.) and a 
MQTT broker. The MQTT feed presents the payload 
information from the IoT-enabled bio-device and is 
displayed in Base-64. This is extracted into a Matlab 
program for this work and displayed in readable ASCII text. 
B. Diagnostic System Details 
  The diagnostic system uses an emerging IoT platform 
(LoRa) to transmit the results from the portable point-of-
care bio-fluid sample analyzer up to a cloud server (via the 
Lorank8 gateway). The point-of-care analyzer is an IoT-
enabled version of the University’s own Qualcomm 
Tricorder XPRIZE finalist device (“Diagnostic reader” 
module shown in Fig. 2) [85]. This diagnostic reader uses 
an optical transmission technique that measures the amount 
of absorption caused by bio activated gold particles as 
controlled by a lateral flow geometry or colour changes due 
to a colorimetric process    Absorption profiles relate to 
qualitative and quantitative measurements of analyses such 
as nitrate-ions (NIT) or leucocytes (LEU) in UTI's. The 
diagnostic reader uses a LoRa chip solution (Microchip 
RN2483) to enable the diagnostic reader to connect to the 
LoRa IoT network. Such technology could help meet the 
needs of the global blood pressure devices market (worth 
US$2b by 2022 [86]), and the global diabetes devices 
market (worth US$35.5b by 2024 [87]). 
The portable LoRa/BLE-enabled electronic diagnostic 
reader (Fig. 2) is an optical transmission-based system that 
can be used to obtain both qualitative and quantitative 
measurements from lateral flow and dipstick tests. The 
LoRa-enabled diagnostic device, together with a disposable 
test ‘key’ (Fig. 3) and companion Android app (depicted in 
Fig. 2), form a diagnostic platform that is capable of 
diagnosing multiple medical conditions rapidly; for this 
trial we emphasize the application of remote healthcare for 
point-of-care screening of urine samples for evidence of a 
UTI. A combination of well-defined clinical symptoms, the 
accessible nature of the urine matrix, and the precedent set 
by existence of a current (albeit error-prone) point-of-care 
test make UTI an appropriate use case for demonstration of 
improved point-of-care diagnostics.  
This diagnostics platform is however not limited to UTI 
diagnosis. More complex pathological conditions are also 
amenable to analysis. For these, a lateral-flow, antibody-
based biomarker detection approach has been implemented, 
whereby labelled, biomarker-specific antibodies react with 
patient sample before being detected through accumulation 
of colored label on a detection membrane located in-line 
with the optical transmission system. From a user-
perspective the mode of operation and associated costs are 
similar. Fig. 4 outlines the process flow for the system and 
highlights how the test result is communicated to both the 
mobile app via BLE and to the securer sever via LoRa 
radio. The main drivers include low cost, ease of use, long 
shelf life, and evolving specificity and sensitivity [88]. Such 
tests enable the detection of biological molecules, or 
biomarkers, which are associated with both pathological 
and non-pathological medical conditions. Typical sample 
sources for point-of-care testing include patient urine, blood 
or saliva, and diagnostic specificity is typically engendered 
through chemical reactions. 
Historically strips have been visually assessed ‘by eye’ 
for visible color change on the strip to deliver qualitative or 
semi-quantitative detection of biomarkers using a chemical 
dye reaction or accumulation of colored nanoparticles on a 
specific region of the test strip. However, if some form of 
electronic detection is used then some tests are capable of 
delivering fully quantitative diagnostic measurements.  
A number of different electronic reading techniques have 
been implemented, ranging from charge-coupled device 
(CCD) imaging [89], reflectance, or transmission [90] mode 
analysis of test strips. For reliable point-of-care use, the 
challenge is to produce a robust portable device capable of 
fully quantitative analysis and preferably allowing 
dissemination of results. We report here on the initial use of 
the diagnostic reader to obtain qualitative data from 
disposable test ‘keys’. The patient sample is added to these 
keys before being placed into the reader. The key comprises 
the biomarker detection strip positioned within a custom 
ABS plastic housing, designed for secure engagement and 
optical alignment into the diagnostic reader. A 
transmission-based optical sensing technique is utilized for 
measurement using an illumination light emitting diode 
(LED) oriented geometrically opposite a photodetector. 
Upon insertion of the test key the optical path between 
illumination LED and photodetector is occluded, with 
biomarker detection resulting in a color change that alters 
strip absorbance and hence the number of photons detected 
by the photodetector. To achieve maximal sensitivity the 
illumination LED and photodetector were both optically 
matched both to each other, and selected to give maximum 
response over the expected range of color change reactions 
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exhibited by the urinalysis dipstick. 
This was achieved by using a scanning 
spectrophotometer to generate absorption spectra for ‘post-
reaction’ test strips. Absorption maxima were identified for 
strips exhibiting a ‘positive reaction’ (assessed by visual 
comparison of the reacted strip with a urinalysis color 
chart); these were then used as criteria for selecting the 
wavelength of the Transmission LED and photodetector 
(data not shown). 
C. Urinary tract infections as a user case 
UTIs are typically caused by either Escherichia coli 
bacteria or associated with abnormalities of the urinary tract 
that disable the patient’s natural defences leading to tissue 
injury; symptoms of urinary tract infections include painful 
urination, frequent urination, or loin pain [91]. It is 
estimated that 35% of women suffer urinary tract infection 
symptoms at some time in their life. Although UTI 
symptoms and treatment are straightforward, for some, 
particularly the elderly, symptoms may not be clear enough 
to immediately diagnose. A wait of several days between 
obtaining a urine sample and receiving laboratory results 
can delay treatment potentially leading to more serious 
health implications. Point-of-care urinalysis dipsticks are 
readily available and have been shown to be useful to 
rapidly identify or rule out infection. Measurement from 
these strips is semi-quantitative and somewhat subjective 
since it involves manual alignment of the wetted strip with 
a color chart for visual assessment of the intensity of color 
development. 
In this trial a ‘test key’ containing two sample windows 
holds a Urinalysis Strip (Suresign Professional, CIGA 
Healthcare, Ballymena, Northern Ireland). The strip 
possesses several biomarker detection zones, two of which 
are sensitive to either urinary NIT (produced by the action 
of Gram-negative bacteria in the urine), or urinary 
Leucocyte esterase (LE) (an enzyme released from 
granulocytic white blood cells as part of the innate immune 
response).  A single drop of urine is placed into each 
sample window on the test key where it is rapidly absorbed 
into the paper-based detection substrate for reaction with 
the test zones. Pathological urine will cause formation of 
strip-localized colored dye compounds within 2 minutes, 
leading to a change in optical absorbance. 
As the diagnostic biosensor was to be used as a first level 
screening test, it was necessary for it to be able to 
discriminate between healthy and pathological urine 
samples. This was achieved through the creation of a 
diagnostic threshold - an experimentally derived sensor 
output value, against which unknown samples could be 
assessed. To maximize sensitivity, a diagnosis of UTI was 
made only when a sample was positive for both NIT and 
LEU activity. 
A series of samples were prepared to enable correlation 
of diagnostic reader’s sensor output with urinalysis results. 
These samples contained increasing concentrations of either 
NIT or LEU reactive compounds, chosen to span the 
healthy to pathological concentration range. An example 
using NIT-containing solutions (Sigma 72587 - NIT 
standard solution) is shown in Fig. 5, where a 
concentration-dependent variation in diagnostic reader 
sensor output can be observed.  Similar work was 
performed to establish the sensor response to the LEU 
reactive portion of the test strip (results not show). 
 Following urinalysis by diagnostic reader the strips 
were immediately subject to visual scoring using either the 
relevant NIT or LEU portion of the manufacturer-provided 
urinalysis color comparison chart. Examples of post-test 
NIT test pad regions are shown in Fig. 5. Samples were 
scored as either positive or negative (+ or -), as indicated 
above each sample pad insert on Fig. 5.  
By selecting a diagnostic reader sensor output value from 
within the range between the highest negative and lowest 
positive sample (as established through visual scoring using 
the urinalysis color chart) it was possible to set the 
‘diagnostic threshold’. This is indicated by the horizontal 
TABLE I 
Comparison of available enabling wireless technologies 
 
[35] LoRa 868/915MHz 50kbps 25Km 14dBm
[36] Sigfox 868/915MHz 300bps 50Km 14dBm
[37] Bluetooth 4 2.4GHz 1Mbps 0.1Km 0/4/10dBm
[38] Bluetooth 5 2.4GHz 2Mbps (125Kbps for PHY) 0.25Km (0.8Km for PHY) 0/4/10/20dBm
[39] ZigBee 2.4GHz  250kbps 10-100m 12dBm
[40] 4G 800, 1800, 2600MHz 12Mbps 10Km 23dBm
[41] 5G Lower bands 3.6Gbps 10Km 23dBm
[41] 5G Higher bands 10Gbps <1Km 23dBm
[42] NB-IoT (NB1) 900MHz 250 kbps 35km 20/23dBm
[43] Z-Wave Alliance  900MHz 9.6/40/100kbps 30m 0dBm
[44] Wi-Fi 2.4GHz and 5GHz 802.11(b) 11M; (g) 54M; (n) 0.6, (Gac) 1Gbps 50m 15dBm
[45] NFC 13.56MHz 100–420kbps 10cm 23dBm (NF)
[46] EC-GSM 900MHz 140kbps 100Km 20/23dBm
[42] LTE-M (M1) 700, 1450 - 2200, 5400MHz 0.144Mbps 35km 20/23dBm
Typical                 
transmit power
Frequency of                  
operation (EU/US)
IoT technology Data rate
Upper                
operating range
cover line on Fig. 5. Any unknown sample yielding a 
diagnostic reader sensor output value greater than the 
threshold values for both NIT and LE was considered to be 
UTI positive. The robustness of this threshold approach was 
assessed independently using a set of blinded positive and 
negative patient samples, achieving a 92.7% correct rate.  
The UTI detection threshold was input to the companion 
Android ‘app’ and transmitted, together with test duration 
and type, to the diagnostic reader via BLE. The diagnostic 
reader then analyzes any inserted UTI test key according to 
these transmitted parameters. A positive diagnosis from this 
diagnostic strip requires that absorbance measurements 
from both NIT and LE regions of the strip be correlated. 
The photodiode output signal was therefore continuously 
communicated to the companion app, upon completion of 
the test the final photodiode outputs for both detection 
regions are compared against the thresholds. A single test 
result (positive or negative) was then communicated to the 
secure server using LoRa, the results of which were 
observed via the MQTT broker (Fig. 6). A series of both 
control and known pathological urine samples were used to 
demonstrate the diagnostic performance of the diagnostic 
reader system. 
III. TEST PLAN AND METHODOLOGY 
The tests were conducted over 3 sites (one rural, one 
urban, and one suburban) and at 3 selected locations around 
each of the sites (see Fig. 7 - 9 for details.). For each of 
these locations two test strips giving a 
“RESULT_POSITIVE” and “RESULT_NEGATIVE” 
outcome were used. This totaled 18 tests in all. All tests 
were conducted in the bathroom of each property due to the 
nature of the test. 
For location 1 (Fig. 7) the base-station/gateway was 
located in Coleraine, UK with GPS co-ordinates N55º 6' 
47.21", W6º 39' 16.22". The antenna mounted on outside 
mounting at 2.3 m above the ground. The location is an area 
of dense forestry (mostly 15m+ Ash trees) which itself is 
surrounded by fields and hills, thus highlighting operation 
in difficult rural terrain. The diagnostic system was tested at 
the 3 locations marked on the map. Test site 1.1 was a 
concrete block residential dwelling (detached bungalow) of 
1970s construction to the East of the base-station with GPS 
co-ordinates N55º 6' 16.08", W6º 34' 10.28". Test site 1.2 
was a two story farm house of 1990s construction 
surrounded by fields to the West of the base-station with 
co-ordinates N55º 6' 1.72", W6º 43' 5.03". Test site 1.3 was 
a two story semi-detached house in a rural farming area 
(1960s) and to the North of the base-station with co-
ordinates N55º 10' 0.26", W6º 38' 21.63".  
For location 2 (Fig. 8) the gateway was located at the 
heart of the city of Belfast with GPS co-ordinates N54º 35' 
47.79", W5º 55' 54.31". The antenna mounted on outside 
mounting at 20 m above the ground. The location is a 
densely populated urban area surrounded by heavy industry 
(including shipping) and emphasizes operation in a busy 
modern city. The diagnostic system was tested at the 3 
locations marked on the map (Fig. 8). Test site 2.1 was a 
three story brick town house of 1930s construction to the 
South of the base-station with GPS co-ordinates N54º 35' 
15.12", W5º 55' 27.02". Test site 2.2 was a retirement fold 
(sheltered housing community) consisting of single story 
apartments 1990s construction to the North of the base-
station with GPS co-ordinates N54º 36' 44.50", W5º 55' 
31.04". Test site 2.3 was a two story large detached house 
in an established residential area erected in the 1950s and to 
the East of the base-station with GPS co-ordinates N54º 36' 
23.95", W5º 52' 56.61". 
For location 3 (Fig. 9) the gateway was located at UU, 
BT37 with GPS co-ordinates N54º 41' 15.72", W5º 52' 
41.24". The antenna mounted on outside mounting at 6 m 
above the ground. The location is a large university campus 
area surrounded by suburban housing. This location 
examines operation in the leafy suburbs. The diagnostic 
system was tested at the 3 locations marked on the map 
(Fig. 9). Test site 3.1 was a concrete block detached 
bungalow dwelling of early 1970s construction to the West 
of the base-station with co-ordinates N54º 41' 35.26", W5º 
56' 11.98". Test site 3.2 was a large detached two story 
house of mid 1990s construction in are large housing 
development to the South of the base-station with co-
ordinates N54º 39' 54.92", W5º 54' 5.95". Test site 3.3 was 
a two story detached house in an established residential area 
erected in the 1950s and to the North of the base-station 
with GPS co-ordinates N54º 42' 10.63", W5º 52' 33.59". 
Fig. 6. Screenshot of MQTT broker used to observe server data 
 
Fig. 5. Diagnostic reader response to increasing NO2 concentration  
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IV. RESULTS AND DISCUSSION 
The measurements were recorded as per the protocol 
above. The secure server recorded the outcome of the test, 
the received signal level power (in dBm), the sequence 
order of the test, and the time and date of the recording. For 
clinical purposes this would allow the identification of the 
patient and subsequent automated Electronic Health Record 
(EHR) input.  
A. Diagnostic system test results  
Results presented in Table II clearly indicate that the new 
diagnostic system operated correctly during all the tests, 
giving correct results based on the particular inserted UTI 
test strip. This was confirmed through visual assessment of 
test strip with the urinalysis chart provided by the dipstick 
manufacturer. The advantage of the electronic analysis of 
strips is that each strip is held in the correct orientation for 
analysis under defined lighting conditions within the reader. 
The reader analysis is based, not on human interpretation, 
but on comparison with an experimentally defined 
threshold. This removes the subjective nature of 
conventional point-of-care dipstick urinalysis which 
requires users to make a judgement based on multiple 
colour intensity comparisons, and correctly interpret results.   
Although the content of this report concerns UTI diagnosis 
the diagnostic methodology for this reader is substantially 
the same for pathologies including bacterial pneumonia, 
anaemia and HIV. Laboratory and field trials for such 
conditions have been conducted using the diagnostic reader 
as part of the Qualcomm Tricorder XPRIZE competition.  
Results were transmitted via the LoRa network to the 
secure server, and presented correct data (including test 
results, date and time, received radio power level, signal to 
noise ratio, gateway identification, transmission frequency, 
and packet number) onto the servers for observation and 
confirmation. The system was designed specifically for use 
by a patient and assumed the patient has little or no IT 
ability. The system is simple to use and should something 
untoward occur during testing the patient user can simply 
cycle the power on the unit and start again. However the 
new LoRa-enable diagnostic reader operated correctly 
during all the community UTI trials. 
For each test activity the system determined and 
transmitted the correct results based on the inserted UTI test 
strip. The signal from the diagnostic system connected with 
the nearest LoRa gateway and the gateway routed the 
results and other test-related information in the correct 
manner to the specified secure server. Using the MQTT 
(example in Fig. 6) the server record was observed and 
verified as accurate in terms of test results, the transmitted 
date and time, the gateway identification listed, the 
transmission frequency (automatically selected by the LoRa 
radio system), packet number, and received radio power 
levels at the gateway. Thus it was confirmed that all 
locations sent back correct data to the secure server. These 
results across various regions and locations within those 
regions clearly demonstrate the opportunity to realize 
secure remote healthcare which requires no subscription 
fees, SIM cards, access to the 3G/4G mobile network, Wi-
Fi access, or an operational landline in the property. 
 
Fig. 7.  Test area 1 (Rural location) 
 
 
Fig. 8.  Test area 2 (City location) 
 
 
Fig. 9.  Test area 3 (Suburban location) 
B. Analysis of the communications channel  
If the remote healthcare solution is required to operate in 
all environments, terrain, and scenarios it is important to 
understand the quality of the communications channel. The 
remote healthcare system is targeted for deployment in 
domiciliary care environments; therefore we present the 
following long range network parameters to determine 
signal robustness and quality of service; received signal 
strength level, effective path losses between device and 
base station, signal-noise ratio, and the path loss exponent. 
The received signal strength level (RSSI) at the base-station 
from the transmitting diagnostic system allows us to 
determine the quality of the secure radio link based on the 
separation distance and the terrain between diagnostic 
system and base-station site. The signal-noise ratio (SNR) 
also acts as an indicator of link quality with respect to the 
radio channel’s environmental parameters. It is the ratio of 
the power of the information signal and the power of 
incoherent background noise, mathematically expressed as; 
 
𝑆𝑁𝑅 =  
𝑃𝑠𝑖𝑔𝑛𝑎𝑙
𝑃𝑛𝑜𝑖𝑠𝑒
         (1) 
 
where P is average power for each expression when the 
power of both signal and noise is considered over the same 
bandwidth of interest. Furthermore each of the values are 
often expressed in decibels; 
 
𝑃𝑠𝑖𝑔𝑛𝑎𝑙(𝑑𝐵) = 10 log10(𝑃𝑠𝑖𝑔𝑛𝑎𝑙)            (2) 
 
𝑃𝑛𝑜𝑖𝑠𝑒(𝑑𝐵) = 10 log10(𝑃𝑛𝑜𝑖𝑠𝑒)          (3) 
 
And subsequently the SNR can be expressed as decibels; 
 
𝑆𝑁𝑅(𝑑𝐵) =  𝑃𝑠𝑖𝑔𝑛𝑎𝑙(𝑑𝐵) − 𝑃𝑛𝑜𝑖𝑠𝑒(𝑑𝐵)    (4) 
 
Additionally, an understanding of the radio link quality 
can be determined by modelling the path losses using the 
well-recognized Log-distance path loss model. The average 
large-scale path loss for each transmitter-receiver separation 
can be suitably expressed as a function of distance using a 
path loss exponent, n, which is dependent on carrier 
frequency, environment, obstructions, etc. The Log-
distance path loss is given by: 
 
𝑃𝐿̅̅̅̅ (𝑑) = 𝑃𝐿(𝑑0) + 10𝑛 log10 (
𝑑
𝑑0
⁄ )      (5) 
 
where n is the path loss exponent indicating the rate at 
which the path loss increases with distance, do is the close-
in reference distance which is determined from 
measurement close to the transmitter, and d is the 
transmitter-receiver separation distance. The path loss 
exponent (n) can thus be calculated;  
 
𝑛 =  
𝑃𝐿̅̅̅̅ (𝑑) − 𝑃𝐿(𝑑0)
10 log10 (
𝑑
𝑑0
⁄ )
⁄      (6) 
 
The signal losses are caused by natural free space loss 
which occurs as the signal travels through space, as well as 
additional losses of which the most prominent for these 
scenarios would be absorption losses into surrounding 
objects (buildings, trees, etc.) in the communication path. 
Table III presents details of the long range network 
parameters for the tests to help understand the quality and 
reliability of this medical network. It is not sufficient to 
declare that it worked, but crucial to understand the 
parameters by which it worked to ensure a more rigorous 
comprehension of operation. Such parameters including the 
aforementioned RSSI, path loss, SNR, and path loss 
exponent allow the apprehension of how well the wireless 
portion of the medical diagnostic system worked during the 
tests and to appreciate what environmental or operational 
factors compromise the quality of the communications 
channel and inform as to what the limitations of such 
systems may be.  
Results in table III highlight the received signal strength 
of the transmitted signal were each apposite values that 
reflect a dependable system that can operate inside houses 
without issues of signal loss or data-link failure (lead-lined 
houses would cause issues but these would be a rarity and 
issues are circumvented by taking the system beside an 
open window). The best RSSI value (highest received 
power) was observed in test 1.2 and the worst in 2.1; this is 
a reflection on the distances travelled and the environment 
through which the signal traversed from the diagnostic 
system. 
  Signal to noise ratio (SNR) for each test is presented 
and the “-” sign indicates that the signal power is below the 
noise floor threshold. This is one of the key advantages of 
the LoRa technology and allows data to be received below 
power levels where signals are normally lost in the 
background noise (such as is the case with the cell phone 
network). Minus value SNR were observed for 6 of the 9 
test cases. The highest SNR was recorded from test 1.2 and 
the lowest for test 2.1; again an indicator that the wireless 
transmission aspect of the system is less robust in highly 
dense urban areas (although still perfectly functional) and 
best in open rural areas. Additionally the path loss exponent 
(n) for each test is presented with the lowest value observed 
in test 1.2 where the propagating data signal had few 
obstacles in its path towards the base station, whereas 2.1 
had the highest exponent where the signal travelled through 
a dense urban environment with multiple signal absorbers, 
reflectors and scatterers. In each environment the values of 
n measured are in keeping with [92]. 
Fig. 7-9 (and Table III) also detail the path losses 
experienced by the signal carrying the transmitted results 
back to the base station. They clearly highlight that 
regardless of the operational environment for the medical 
diagnostic tester the technology offers a robust method of 
long range secure data transmission. Only test results from 
location 2.1 to the city center base station gave any cause 
for concern as this amount of path loss is close to the 
maximum working limits. However this can be easily 
improved by better positioned base stations with larger 
antennas, as well as more than one base station covering an 
entire city; should such a system be deployed then choice 
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locations would be selected and a typical number of 3 base 
stations would be used to allow additional features such as 
triangulation and elimination of bad reception in density 
packed environments (such as New York). 
C. Other significant findings  
IoT servers typically employ User Datagram Protocol 
(UDP) port numbers such as 1700, but in many large 
organizations (commercial/private networks) such port 
numbers are blocked by the corporate firewall. This causes 
network set-up problems as without access to the particular 
IP address it is not possible to set up two-way 
communications between the base-station and the back-end 
server. For the LoRa network this can be circumvented by 
using one way communications with the base-station 
sending information out (with no receive acknowledgement 
from the back-end server). The other key IoT technology, 
Sigfox, uses a business model more akin to the cell phone 
network where large companies develop the infrastructure, 
therefore corporate firewall and port issues are less of a 
difficulty. However, coverage in remotest areas cannot be 
solved by the end user (as it can for LoRa), instead 
requiring network development by provider. 
Battery life for our testing purposes was not a particular 
issue and in practical operation the system would typically 
be used a few times a day for a period of a few weeks. If 
longer term monitoring is required then emerging energy 
harvesting solutions such as photovoltaic harvesting (solar 
power) could be employed and/or the processing and LEDs 
of the diagnostic reader could be optimized for lower power 
to ensure longer operation from a single battery. 
Alternatively a charging station could be used or a mains 
power supply as such a device is typically used in the same 
place (kitchen or bedroom), however this may affect the 
potential mobility of the user during activities of daily 
living and is thus much less desirable. Energy requirements 
are 200mW when the LEDs are on and 120mW when off. 
Conducting the UTI test takes on average approximately 
225 seconds which mean that the system can be used some 
400 times on one 9v battery (Duracell - 550mAh). To date 
the system is not optimized power consumption; further 
development can only increase the number of tests 
achievable per battery. 
A final point of note regards the operation of the system 
within our biomedical research and development facility. 
The building was constructed with a metal mesh to act as a 
Faraday shield against electromagnetic interference; this 
makes a barrier against signals getting in and out of the 
TABLE II 
URINARY TRACT INFECTION TRIAL RESULTS FOR THE NINE SPECIFIED TEST SITES 
 
Test site 1.1 1.2 1.3
GPS co-ordinates N55º 6' 16.08", W6º 34' 10.28" N55º 6' 1.72", W6º 43' 5.03" N55º 10' 0.26", W6º 38' 21.63"
Device/base-station separation (Km) 5.5 4.3 6.0
Result Positive Confirmed Confirmed Confirmed
Result Negative Confirmed Confirmed Confirmed
Test site 2.1 2.2 2.3
GPS co-ordinates N54º 35' 15.12", W5º 55' 27.02" N54º 36' 44.50", W5 º 55' 31.04" N54º 36' 23.95", W5º 52' 56.61"
Device/base-station separation (Km) 1.1 1.8 3.4
Result Positive Confirmed Confirmed Confirmed
Result Negative Confirmed Confirmed Confirmed
Test site 3.1 3.2 3.3
GPS co-ordinates N54º 41' 35.26", W5 º 56' 11.98" N54º 39' 54.92", W5º 54' 5.95" N54º 42' 10.63", W5º 52' 33.59"
Device/base-station separation (Km) 3.8 3.0 1.7
Result Positive Confirmed Confirmed Confirmed
Result Negative Confirmed Confirmed Confirmed
Location 1   (Rural) (N55º 6' 47.21", W6 º 39' 16.22")
Location 2   (City) (N54º 35' 47.79", W5 º 55' 54.31")
Location 3    (Suburban) (N54º 41' 15.72", W5 º 52' 41.24")
building. While the chances of operating the system within 
such a building arrangement would be rare it should still be 
noted that transmission distances are considerably reduced. 
However as the system is truly portable it is considered that 
the test could be conducted with an open door, or indeed 
conducted in a porch, conservatory, or simply outside. 
V. CONCLUSIONS 
A significant step in realizing the next generation of 
remote healthcare systems has been taken. The 868 MHz 
LoRaWAN-enabled personalized healthcare device 
demonstrated its potential with the UTI test results being 
correctly diagnosed and transmitted to a remote secure 
cloud server in each case. The validity of a medical 
diagnostics system enabled with IoT technology and 
deployed in residential settings has been investigated and 
proven to yield robust telemetry results to the attending 
clinician at the hospital or medical center via the LoRa 
network. The tests ranged over a distance of 1.1 – 6.0 Km 
and displayed radio path losses from 119 – 141 dB. 
Furthermore, all tests conducted were correctly and robustly 
received at the base station and relayed to the secure server 
for inspection. The UTI test strips were visually inspected 
for correct diagnosis based on color change and verified as 
100% correct. Results from both urban and rural 
environments highlight that such a system has the capacity 
to be deployed in any part of a country. Such technology 
can foreseeably make a genuine impact on how patients 
with chronic conditions are monitored, and using this 
developed solution as a platform it is possible to enable any 
monitoring or medical device with the same remote 
capability. As the Lora network infrastructure becomes 
deployed throughout Europe, USA, and beyond there is a 
true opportunity to meet the needs of the global ageing 
population.  
The next step is to characterize the sensitivity and 
specificity of the system against clinically approved 
standards, as well as to put the system in the hands of 
typical target user groups to understand the strengths and 
limitations of using such a system. This will allow us to 
 
TABLE III 
URINARY TRACT INFECTION TRIAL DETAILS FOR THE LONG RANGE WIRELESS TRANSMISSION OF TEST RESULTS TO THE SECURE SERVER 
 
Test site 1.1 1.2 1.3
Device/base-station separation (Km) 5.5 4.3 6.0
Frequency channel (MHz) 868.5 868.3 868.5
RSSI (dBm) -109 -105 -114
Path loss (dB) 123 119 128
SNR (dB) 1.1 2.0 -4.2
n 2.5 2.4 2.6
Test site 2.1 2.2 2.3
Device/base-station separation (Km) 1.1 1.8 3.4
Frequency channel (MHz) 868.1 868.3 868.3
RSSI (dBm) -127 -114 -124
Path loss (dB) 141 128 138
SNR (dB) -17.2 -6.8 -12.5
n 3.6 3.0 3.1
Test site 3.1 3.2 3.3
Device/base-station separation (Km) 3.8 3.0 1.7
Frequency channel (MHz) 868.1 868.1 868.5
RSSI (dBm) -121 -116 -113
Path loss (dB) 135 130 127
SNR (dB) -16.0 -12.5 1.7
n 2.9 2.8 3.0
Location 1   (Rural) (N55º 6' 47.21", W6 º 39' 16.22")
Location 2   (City) (N54º 35' 47.79", W5 º 55' 54.31")
Location 3    (Suburban) (N54º 41' 15.72", W5 º 52' 41.24")
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evaluate the feasibility of real-world data collection and 
redevelop unfavorable aspects of the technology before 
considering clinical trials.  
We have thus presented a diagnostics system suitable for 
use by a patient who has been sent home from hospital or 
who suffers from a chronic condition. It allows them to 
perform daily tests regardless of whether they live in an 
urban or rural area, have a mobile signal in their area, and 
have a broadband connection or even a landline in their 
home. We have proven that the Internet of Things is a 
promising solution for chronic illness monitoring in the 
community and as a portable solution for travelling 
homecare workers, midwives, etc. 
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